AT
Attovia TherapeuticsAttovia Therapeutics is a clinical-stage biotech developing ATTOBODY-based biotherapeutics for immune-mediated diseases that went public on Nasdaq in August 2026 in an upsized IPO raising ~$332M gross.
8 Pulse stories
CB
Colossal BiosciencesColossal Biosciences is a genetic engineering company working to de-extinct species like the woolly mammoth and dire wolf while commercializing spinout biotech applications.
3 Pulse stories
Total Raised
~$588M ($256M private + $332M IPO gross incl. greenshoe, Aug 2026)
$850M
Attovia TherapeuticsColossal Biosciences
Last Valuation
$767M at IPO pricing; ~$904M market cap at Nasdaq open (Aug 5, 2026)
$10.3B
Attovia TherapeuticsColossal Biosciences
Biotech
Sector
Biotech
2023
Founded
2021
San Carlos, CA
HQ
Dallas, Texas
Public (ATTO)
Status
Private
Attovia Therapeutics investors
venBio PartnersGoldman Sachs AlternativesFrazier Life SciencesDeep Track CapitalIllumina VenturesSanofi VenturesEcoR1 Capital
Colossal Biosciences investors
TWG GlobalThomas TullMark WalterTim DraperWinklevoss CapitalIn-Q-TelARCH Venture PartnersTom Brady
Data from Value Add Pulse coverage and company research — see the full threads for Attovia Therapeutics and Colossal Biosciences.